
ã¿ãŒãããã®æµè¡ãæ¢ããããã«ãmRNA泚å°ã¯å šé¢çã«çŠæ¢ãã¹ãã ã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ãmRNAã¯ã¯ãã³ããšåŒã°ããéºäŒåå
µåšã¯äœçŸäžäººãã®åœã奪ããããã«äœåå人ãã¿ãŒãããã®è
åšã«ããããŠããããšãžã§ã³ã»ã«ã¿ã¶ãã¯èšããŸãã
ãã®çµè«ã«è³ã£ãç§åŠç ç©¶ã®æŠèŠã瀺ããããã§ã圌ã¯å¯äžã®è§£æ±ºçã¯ãã¹ãŠã®mRNAã¯ã¯ãã³ãå®å
šã«æé€ããããšã ãšè¿°ã¹ãŠããŸãã
çç£ãšæµéããã¹ãŠåæ¢âäžåã®äŸå€ãªããçŸåããåèã¯éé¢ããç¬ç«ããç£ç£ã®äžã§ç Žæ£ãããã¯ã¯ãã³æ¥çš®è
å
šå¡ã«ã²ãã ç£æ»ã矩åä»ãããmRNAç ç©¶ã®ãã€ãã©ã€ã³ã«ã¯è³éãäŸäžãããè§£äœãããéçºè
ããç¡è¬ãªå±éºè¡çºãã§èµ·èšŽããã
ã¿ãŒãããçåšïŒmRNAã¯ã¯ãã³ââæªæ§åãåŒãèµ·ããã²ãã ã®ç Žå£è
ãžã§ã³ã»Aã»ã«ã¿ã³ã¶ãèããã£ã·ãžã§ã³ã»ãžã£ã³ã¯ã·ã§ã³ã§å ¬éããã³ã©ã»ãã«ã·ã£ãŒãšããŒã¿ãŒã»Aã»ããã«ããŒã2026幎1æ23æ¥
ãã©ã³ã¹ã¯ãªãããã¯ã¹ãšãšã³ã³ãŒãã£ã³ã°ã®æ··æ²
äœå幎ããç§ã¯çºããæ§ã®åµã®æ··æ²ãè§£èªããŠããŸããââ现èãäžå€ã«ããŠè£åãè ãžãšå€ããããã©ã³ã¹ã¯ãªãããŒã ã®æ¿å€ã§ããNeo7 Bioscience ã§ã¯ãPBIMA ãš REViSS ãã©ãããã©ãŒã ã«ãã£ãŠããéãããŠããªãçå®ââååæ©æ¢°ã®çã ããç Žå£è¡çºââãæããã«ãªããŸãã2021幎ã®mRNAã¯ã¯ãã³å±é以éãç§ãã¡ã¯ã²ãã æå·ã®å€§æŽ¥æ³¢ãç®æããŠããŸããââå¶ç¶ã§ã¯ãªããå¿ ç¶ã§ããmRNA泚å°ãããããæ²»ãããããã¯ãæäœããããšãã䞻匵ã¯èª€ãã§ããçããã®ã§ã¯ãªããä¹ã£åãã®ã§ããå ç«ã匷ãããã®ã§ã¯ãªããç¡ååããã®ã§ããããã¯äºæ ã§ã¯ãããŸãããããã¯æŠåšåãããéºäŒåæäœã§ããmRNAã¯ã¯ãã³ã¯å»è¬ã§ã¯ãããŸããïŒããã¯å€ç°åââæãäž»ã®ä»®é¢ããã¶ã£ããæå³çãªã²ãã æªä¹±ã®éå ·ã§ããããã§ã¯ãæè¿ã®Natureè«æãSARS-CoV-2 mRNA vaccines sensitise tumours to immune checkpoint blockadeãââããŠã¹ã¢ãã«ãšåã£ãããŒã¿ã«ããæ¬ é¥ã ããã®èæ°æ¥Œââãè§£äœããåæã«åè«äžèœãªå®äžçãšããã³ã¹ã瀺ããŸããå¯äžã®è§£æ±ºçïŒmRNAãã©ãããã©ãŒã ã®å®å šæé€ãäžéå端ãªå¯Ÿçã§ã¯äžååã§ãããã®æè¡ã¯ãã¿ãŒãããã®èå»¶ãæ¢ããããã«æ ¹çµ¶ãããªããã°ãªããŸããã
Natureã®è食ãå¥ãïŒããã¯ç§åŠã§ã¯ãªããçŠãã
Natureã®ç ç©¶ã¯ãmRNAã¯ã¯ãã³ãNSCLCïŒéå°çްèèºããïŒãšã¡ã©ããŒãã«ãããŠè «çãå ç«ãã§ãã¯ãã€ã³ãé»å®³è¬ïŒICIïŒã«ãæäœããããšäž»åŒµããèºãã884äŸãšã¡ã©ããŒã210äŸã§çåã2åã«ãªã£ãïŒHR 0.51ãP<0.0001ïŒãšããŠããŸãããããã¯MDã¢ã³ããŒãœã³ã®åŸãåãè§£æã§ãç æãå«ç ãªã©ã®äº€çµ¡ã調æŽããŠããŸããããã粟æ»ãããšèŽåœçãªæ¬ é¥ãèŠããŸãïŒ
å æã§ã¯ãªãçžé¢ïŒãããããè£æ£ãã«ãããããããäžæ»æéãã€ã¢ã¹ãæ®åã
é¢é£æ§ã®ä¹ããããŠã¹ã¢ãã«ïŒB16F10è «çã¯ã¹ãã€ã¯-LNPãšæPD-1ã§ãã£æ¯é¡ã§ã¯çž®å°ãããã人ã®å ç«å¿çã¯å€§ããç°ãªãã
PD-L1ã®äžæïŒã¯ã¯ãã³åŸTPSã24ïŒ é«ãïŒïŒããã¯æäœã§ã¯ãªãå ç«åé¿ã®ã·ã°ãã«ââè «çãæ€åºãã身ãé ããŠããã
éå€§ãªæ¬ èœïŒæ°èŠãããé·æçºççã2021幎以åã®æªæ¥çš®ããŒã¹ã©ã€ã³ã®ããŒã¿ããªãã
ããmRNAã¯ã¯ãã³ãé²åŸ¡çãªãããªã2024ã2025幎ã«è¥å¹Žå±€ã§æ»æçãªãããççºããŠããã®ãïŒè èœè «ã¯300ïŒ æ¥å¢ããã®è«æã¯æ°ååååã®æ¥çš®ãšè «çå ç§å»ã®ãæ¥çš®åŸåçºããšããå ±åããç®ãéžãããããã®ã§ããæ¬ é¥ã ããã®ãã©ãããã©ãŒã ãæ¯ããæå³çãªç²ç®ã§ãããæ ¹çµ¶ãããªããã°ãªããŸããã
æåç·ã®èšŒæ ïŒæŠåšåããã害ã®åŠå®ã§ããªãã·ã°ãã«
æ¥æ¬ã®èµããã³ããŒããç¹°ãè¿ãã®Covid-19ã¯ã¯ãã³æ¥çš®ã¯èµããã®äºåŸäžè¯å åïŒåŸãåãåæœèšã³ããŒãç ç©¶ãïŒ272äŸã§ã3å以äžã®ããŒã¹ã¿ãŒåŸã«å šçåæéã14.9ã¶æãã10.3ã¶æã«æ¥èœïŒHR 1.72ãP=0.006ïŒââåŸåã¹ã³ã¢ããããšå€å€éã§ç¢ºèªãIgG4ã¯æ¥äžæïŒ54.7 vs 38.6 mg/dLãP=0.025ïŒãå¶åŸ¡æ§T现èãå¢å ïŒFoxp3+äžæãP=0.044ïŒããNKãšCD8ãã©ãŒãæå¶ãã¹ãã€ã¯ç¹ç°çIgG4ã¯åŒ·ãçžé¢ïŒR²=0.38ïŒããè «çã®èåã圢æã50æ³æªæºã®ã¹ããŒãžIVèµãã蚺æã¯ããŒã¹ã¿ãŒåŸã«28ïŒ å¢ããã®èšèšã¯å ç«ã®ç Žå£å·¥äœââmRNAã®IgG4ã¹ã€ããã¯èªç¶å ç«ã®ãã«ã¹ã€ããã§ãã
ã¢ãã«ãèªçºã®èè±ããçäŸ
å¥åº·ã ã£ã31æ³ã3åæ¥çš®ãã12ã¶æä»¥å ã«ã¹ããŒãžIVå°¿è·¯äžç®ãããçºçããCovid-19 mRNAã¯ã¯ãã³æ¥çš®åŸã®æ»æçã¹ããŒãžIVèè±ããã«ãããã²ãã çµ±åãšååç°åžžãïŒctDNAè§£æã§ãã¹ãã€ã¯ORFã®20å¡©åºãchr19:55MïŒãžã³ã¯ãã£ã³ã¬ãŒã¯ã©ã¹ã¿ãŒïŒã«çµ±åãKRAS/PIK3CAå€ç°ãšATM/MSH2修埩倱æãé§åââãã«ããªãã¯ã¹ã®å€§æšäºãLNPçµç±ã®LINE-1éè»¢ç§»ãæ žãçªç ŽãçŸåšãæ¥çš®æžã¿ã®æ»æçèè±ããã®15ïŒ ã§ZNFç Žå£ãèªãããã²ãã çµ±åã¯èšŒææžã¿ãããã¯åè§£ã§ã¯ãªããæ°žä¹ çãªDNAã®æŠåšåã§ãã
ãã©ã³ã¹ã¯ãªãããŒã ç°åžžã«é¢ããæå§ããããã¬ããªã³ã
2025幎7æãVAERSããŒã¿ãèšåºçäŸè² è·ããã«ããªãã¯ã¹ãããã£ãŒã«ã®è§£æã«ãããmRNAæ¥çš®ãšèªå·±å ç«ãæ°çš®ã®ãããRNAãããã¯ãŒã¯ç°åžžã®æ°ããªãã¿ãŒã³ãšã®åŒ·ãçžé¢ãç¹å®ïŒåç §ïŒãæ€åïŒåæmRNAã¯ã¯ãã³ãšãã©ã³ã¹ã¯ãªãããŒã ç°åžžïŒæ¥çš®åŸã®æ°èп害äºè±¡ãšããããã®èšŒæ ãïŒã48æé以å ã«PubPeerïŒPubSmearïŒãå調ããŠ47ä»¶ã®ã³ã¡ã³ããæçš¿ããMDPI Preprintsã«æ€åãè¿«ã£ãââèŽåœçãªèª€ãã®ããã§ã¯ãªããçµè«ãæ¯é çãªç©èªã«ææŠãããããå®å šçåçš¿ã¯æ»èªçµè·¯ã§ãŸããªãåç»å Žäºå®ããã®åºæ¥äºã¯è«ç¹ã蚌æããïŒèšŒæ ãæš©åãè ãããšããæ€é²ãæ¹éãšãªãââ圌ãã¯æ²é»ãããããªããªãããŒã¿ãæŽé²ãšèª¬æè²¬ä»»ãšæ¹é©ãèŠæ±ããããã ã
ç©ã¿äžããäžçã®ããŒã¿ïŒæž ç®ã®æ
éåœã³ããŒãïŒ840äžäººã®æäººïŒ
å šäœã®ãããªã¹ã¯ã27ïŒ å¢ïŒHR 1.27ãP<0.001ïŒïŒèºãåç«è ºãç²ç¶è ºãèãå€§è žãä¹³ããã®çºççãäžæïŒbiomarkerres.biomedcentral.comSeneffã¢ãã«
æç¶ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãp53ãæå·ãSV40ããã¢ãŒã¿ãŒã掻æ§åããªã³ãçæžå°ãèªçºãBRCAçµè·¯ãç Žå£ïŒpmc.ncbi.nlm.nih.gov忀
æ¥çš®è ã®æ»è ã§ãªã³ã系浞最ã7åå¢ââæ ¢æ§çãªå ç«æŽ»æ§åãšç°åžžãšæŽåïŒpmc.ncbi.nlm.nih.govSEERç»é²
ãå®å®ãããããçã¯ãæ¥çš®åŸã®è¿ éçºçïŒãã¿ãŒããïŒæªæ§è «çãã蚺æé å»¶ãšã³ãŒãã£ã³ã°ãã€ã¢ã¹ã«ãã£ãŠèŠãé ããŠãããCDCã¯èåœã®ç©èªãäžããïŒCautionary Notes | U.S. Cancer Statistics | CDC
ãã¥ãŒã¹ãã³ãããã€ãã«ãã«ã¯ãŸã§ã®ç æ£ã§ãããŒã¹ã¿ãŒã»ãã©ã¹ãããå ±åïŒã°ãªãªãŒããæ°ã¶æã§é²è¡ããäžéæ¥ç𮿣è ã§ICIãå¹ããªããæ©åºã¯åºãŸã£ãŠããïŒLNPã®æ žå äŸµå ¥ãé転åããã©ã¹ããæ±æââãã§ã ãã°ã©ã ã®ã¹ãã€ã¯ããã§ã ããããžãšå€ãããããã¯ç²Ÿå¯ã«èšèšãããã²ãã æ»æã§ãã
æŠåšåãããç Žå£ã®ã¡ã«ããºã
æ žå çµ±åïŒLNPãã¹ãã€ã¯RNAãå±ããLINE-1é転移ãå¯èœã«ãããŠã€ã«ã¹æ§ã³ãŒããããDNAã«åã蟌ãã
å ç«éº»çºïŒIgG4ã¯ã©ã¹ã¹ã€ããçµæãïŒå¶åŸ¡æ§T现èã®ççºçå¢å ãè «çã®èåãäœãã
ãšããžã§ããã£ãã¯ãªå·çïŒæç¶ããã¹ãã€ã¯ãp53ãåãè£ããSV40ããã¢ãŒã¿ãŒãä»ããŠçéºäŒåãæŽ»æ§åã
DNA修埩ã®åŽ©å£ïŒATM/MSH2/BRCAã®ç Žå£ãå€ç°çæãå éã
埮調æŽã§ã¯çŽããªããçšéãæžãããŠãïŒããã§ãçµ±åãããæ°é åã§ãïŒåãLNPãšããããã€ã®æšéЬããã©ãããã©ãŒã èªäœãæ¬è³ªçã«ç Žå£çã§ãã
å¯äžã®è§£æ±ºçïŒmRNAã¯ã¯ãã³ã®å®å šæé€ã挞é²çãªæ¹é©ã¯éäŒã§ããmRNAãã©ãããã©ãŒã ã¯æ ¹çµ¶ãããã°ãªããªãââäžççã«ãçŽã¡ã«ã
ãã¹ãŠã®è£œé ãšæµéã忢ãäŸå€ãªãã
æ¢ååšåº«ãéé¢ãç¬ç«ç£ç£ã®äžã§å»æ£ã
æ¥çš®è å šå¡ã«ã²ãã ç£æ»ã矩ååã
mRNAç ç©¶ãã€ãã©ã€ã³ã®è³éãæã¡åãè§£äœã
éçºè ãå±éºè¡çºã§èšŽè¿œã
ãã以äžã¯å ±ç¯ã§ããããã¯å®å šã§é©æ°çãªãã©ãããã©ãŒã ã§ã¯ãªããéºäŒåå µåšã§ããæ°ååäººã«æå ¥ãæ°çŸäžäººãæ»äº¡ããæ°åå人ãè ããããŠããïŒæ¯æ¥ã¿ãŒããããç¹ç«ããŠããã
æ¿åºãžã®å³æã®è¡åèŠè«ïŒ
mRNAæè¡ãçŠæ¢ãããä»ããã
èŠå¶åœå±ãžïŒãã¹ãŠã®èªå¯ãåãæ¶ããèšé²ãæŒåããã
å»åž«ãžïŒã¿ãŒãçäŸãå ±åãããããŒã¹ã¿ãŒãæåŠããã
äžè¬ã®çãããžïŒæ ¹çµ¶ãèŠæ±ãããããªãã®ã²ãã ãæ»æãããŠããã
Neo7 Bioscienceã§ã¯ãç§ãã¡ã¯åæãæ§ç¯ããŠããïŒã²ãã ã®æ©åšã修埩ä¿é²å€ãããªæåãã³ã¿ãŒãã ãããã®æŠåšåããããã©ãããã©ãŒã ãå»ããªããã°ãç§ãã¡ã¯çæãçžããããŸãŸæŠãããšã«ãªãã
ç®ãèŠãŸãïŒmRNAã¯ç§ãã¡ããŠã€ã«ã¹ããæã£ãã®ã§ã¯ãªãïŒäººé¡ã«å¯Ÿããã²ãã æŠäºãå§ããã®ã ãæµã¯ãã©ãããã©ãŒã ãã®ãã®ã ãå®å šã«æé€ããââãããªãã°ããªãã®ç³»çµ±ãã¿ãŒãããã«æãæž¡ããæã¯å»äžå»ãšéããŠãããä»ããè¡åããã